Vanderbilt University

The University of Mississippi

Asklepion Pharmaceuticals, LLC

Frederick E Barr

Marshall Lynn Summar

Brian W Christman

Reid Carleton Thompson

Marshall L Summar

Gary R Pasternack

Suvankar Majumdar

Gurdyal Kalsi

Judy L Aschner

Candice D Fike

A method for administration of citrulline for the treatment of sickle cell disease and other complications of sickle cell disease thereof.

Citrulline for treatment of sickle cell crisis

This invention provides methods for treating endothelial dysfunction by administering an effective amount of citrulline to a patient. The patients may be suffering from acute respiratory distress syndrome (ARDS), sepsis, or infection by COVID-19 (Coronavirus Disease 2019); COVID-19 patients may be at risk of developing endothelial dysfunction, or they may be experiencing endothelial dysfunction. The effective amount of citrulline is sufficient to reduce the uncoupling of endothelial nitric oxide synthase (eNOS) or to reduce the formation of free radicals. Citrulline may be administered orally; intravenously; or both orally and intravenously in a sequential manner. Sequential administration of citrulline may be in three phases, such as (a) an initial phase in which citrulline is administered orally, (b) an intermediate phase wherein citrulline is administered intravenously, and (c) a final phase wherein citrulline is administered orally. The intermediate phase may be while the patient's breathing is being assisted mechanically.

Action of L-citrulline to prevent or treat endothelial dysfunction

A method for administering citrulline to a patient during surgery without filtration of the hemolysis.

Intravenous administration of citrulline during surgery

Methods and compositions for treating a complication associated with aneurysmal subarachnoid hemorrhage (SAH), the method comprising administering an effective amount of a nitric oxide precursor to a subject in need thereof. Methods and compositions for treating vasospasm, the method comprising administering an effective amount of a nitric oxide precursor to a subject in need thereof.

Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage

Isolated polynucleotide molecules and peptides encoded by these molecules are used in the analysis of human carbamyl phosphate synthetase I phenotypes, as well as in diagnostic and therapeutic applications, relating to a human carbamyl phosphate synthetase I polymorphism. By analyzing genomic DNA or amplified genomic DNA, or amplified cDNA derived from mRNA, it is possible to type a human carbamyl phosphate synthetase I with regard to the human carbamyl phosphate synthetase I polymorphism, for example, in the context of diagnosing and treating hepatic veno-occlusive disease (HVOD) associated with bone marrow transplants.

Growing community of inventors

Nashville, TN, United States of America

Frederick E Barr